Open AccessSalvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results
Author(s) -
G Raguin,
Gwendoline Poizat,
Laurence MorandJoubert,
AnneMarie Taburet,
Clotilde Le Tiec,
François Clavel,
Geneviève Chêne,
PierreMarie Girard
Publication year - 2007
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3280118d6a
Subject(s) - amprenavir , lopinavir , ritonavir , lopinavir/ritonavir , virology , medicine , salvage therapy , reverse transcriptase inhibitor , viral load , sida , viral disease , human immunodeficiency virus (hiv) , biology , chemotherapy , antiretroviral therapy , enzyme , protease , biochemistry , hiv 1 protease
We report the results of the extended follow-up at one year of a randomized trial evaluating the virological efficacy of a salvage therapy combining lopinavir and amprenavir with either 200 or 400 mg/day ritonavir, along with optimized nucleoside reverse transcriptase inhibitors, in patients carrying multidrug-resistant isolates. The combination of amprenavir, lopinavir and ritonavir (400 mg/day) is durably potent, yielding a sustained virological response (HIV RNA < 50 copies) in 39% of cases.